In a statement, AVAC welcomed the groundbreaking results of the PURPOSE 1 HIV prevention study of a twice-yearly injection of lenacapavir among adolescent girls and young women in South Africa and Uganda. 

“This is one of the most important results we’ve seen to date in an HIV prevention study,” said Mitchell Warren, AVAC’s executive director. “Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most – from an easier to follow regimen for individuals to a decreased burden on healthcare systems that are stretched to the limit.” 

Calling on Gilead Sciences, which makes the drug, and regulatory agencies to fast-track regulatory review of the new prevention method, Warren added, "There is no time to waste if we are to translate these exciting clinical trial results into actual public health impact and expand the toolbox of HIV prevention choices” ... Read More